A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer

Exclusion Criteria

• •Postoperative wound healing is poor and chemotherapy is not appropriate to start
• •Recurrent patients or suspected peritoneal metastases after radical surgery
• •Known DPD enzyme deficiency
• •Allergy to, or history of severe allergy to, or contraindication to any of the experimental drugs or its excipients
• •Patients who are expected to require major surgery during the study period
• •Congenital pulmonary fibrosis, drug-induced pneumonia, organized pneumonia, or CT-confirmed active pneumonia
• •Tested positive for HIV
• •Active hepatitis b or c
• •Only liquid diet was allowed after the operation, with BMI \<18kg/m2
• •Uncontrolled pain
• •A history of antitumor drug therapy other than radical surgery
• •Severe infection in the active stage or with poor clinical control
• •Use of hormones is contraindicated
• •Severe cardiovascular disease, myocardial infection or cerebrovascular accident, arrhythmia, unstable angina pectoris within 3 months before the trial
• •Uncontrollable increase in blood pressure or blood sugar
• •A history of other malignancies within 5 years, except for carcinoma in situ of the cervix, non-melanoma skin cancer, or stage I uterine cancer
• •Distant metastases are known
• •Peripheral neuropathy ≥ NCI CTCAE grade 2
• •Serum albumin \< 2.5 g/dL
• •Chronic enteritis
• •Any other disease for which there is evidence of a need to limit the use of experimental drugs
• •Participate in additional trials up to 30 days before the trial or plan to participate in additional trials while the trial is ongoing
• •Receive other experimental drugs up to 28 days before the start of the trial
• •Women who are pregnant or nursing, or who plan to become pregnant within five months of the end of treatment. Women of childbearing age should receive a blood/urine pregnancy test 7 days before the start of the trial
• •Clinically significant active bleeding
• •Patients who have trouble swallowing tablets
• •Previous allogeneic bone marrow transplant or organ transplant